US-UK Pharma Deal Exempts Exports from Tariffs for NHS Threshold Rise

The United States and the United Kingdom announced a trade agreement on Monday that exempts British pharmaceutical exports from American tariffs in exchange for the UK's National Health Service increasing its spending threshold on new medicines by 25 percent. The deal, finalized in Washington and London, aims to balance pharmaceutical trade practices and enhance access to innovative treatments for patients in both countries.

Under the agreement, the US will impose zero tariffs on UK-origin pharmaceuticals, ingredients, and medical technology for the remainder of President Donald Trump's term, sparing exports valued at approximately $3.5 billion annually. This exemption covers potential duties under Section 232 of the Trade Expansion Act, which addresses national security concerns, and Section 301, which targets unfair trade practices. In return, the UK's National Institute for Health and Care Excellence will raise its cost-effectiveness benchmark for approving drugs from 20,000 to 30,000 pounds per quality-adjusted life year to 25,000 to 35,000 pounds, the first major adjustment in over two decades. The change, effective in April, is expected to allow three to five additional...